Mineralys Therapeutics strengthens its board with two commercial experts as the company approaches a critical December 22 regulatory milestone for its drug candidate, lorundrostat.
Mineralys Therapeutics announced the appointment of two new board members with commercial experience ahead of a PDUFA date, which is a neutral corporate governance update.
Mineralys Therapeutics has appointed Ms. Peterson and Mr. Coats to its board of directors, bolstering the company's commercial and product launch expertise. The strategic move comes as the firm prepares for the December 22 PDUFA target action date for its lead candidate, lorundrostat.
The company added Ms. Peterson and Mr. Coats to provide additional commercial and product launch experience ahead of the upcoming regulatory decision for lorundrostat.